A biomarker investigation for the recurrence and/or activity of recurrent glomerulonephritis in renal transplant recipients

A biomarker investigation for the recurrence and/or activity of recurrent glomerulonephritis in renal transplant recipients - A biomarker investigation for the recurrence and/or activity of recurrent glomerulonephritis in renal transplant recipients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015773

Enrollment

100

Registered

2014-12-01

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney transplant recipients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Recipients who are scheduled allograft biopsy and agreed with the study

Exclusion criteria

Exclusion criteria: 1) Patients without agreement 2) Patients who are under 16 years-old

Design outcomes

Primary

Measure	Time frame
Pathological diagnosis of post-transplant IgA deposition in the allograft and its activity (Oxford classification, pathological severity score of Japanese Society of Nephrology, and the existence/ absence of crescent formation) : At the time of allograft biopsy	—

Secondary

Measure	Time frame
1) Serological IgA activity (galactose-deficient IgA1, galactose-deficient IgA1-specific IgA, galactose-deficient IgA1-specific IgG, and immune complex of galactose-deficient IgA1 and galactose-deficient IgA1-specific IgA/IgG) 2) Urinary WT1-positive cells and CD68-positive cells 3) Type of the original disease for end stage renal disease 4) Pathological expression of CD71 (IgA receptor) in the mesangial cells 5) Banff classification score, the existence of fibrous intimal thickening of interlobular artery, and glomerular sclerosis index 6) Urinary angiotensinogen 7) The type, dose, blood concentration and AUC of immunosuppressants 8) Allograft function (eGFRCr and eGFRCys) 9) Urinary protein excretion, urinary albumin excretion, urinary occult blood, urinary NAG and microscopic urinalysis 10) Blood pressure and the type and dose of antihypertensive drug(s) 11) Blood biochemical test 1~7: at the time of allograft biopsy 8~11: at the time of allograft biopsy, and 1 and 2 years after allograft biopsy	—

Measure

Time frame

1) Serological IgA activity (galactose-deficient IgA1, galactose-deficient IgA1-specific IgA, galactose-deficient IgA1-specific IgG, and immune complex of galactose-deficient IgA1 and galactose-deficient IgA1-specific IgA/IgG) 2) Urinary WT1-positive cells and CD68-positive cells 3) Type of the original disease for end stage renal disease 4) Pathological expression of CD71 (IgA receptor) in the mesangial cells 5) Banff classification score, the existence of fibrous intimal thickening of interlobular artery, and glomerular sclerosis index 6) Urinary angiotensinogen 7) The type, dose, blood concentration and AUC of immunosuppressants 8) Allograft function (eGFRCr and eGFRCys) 9) Urinary protein excretion, urinary albumin excretion, urinary occult blood, urinary NAG and microscopic urinalysis 10) Blood pressure and the type and dose of antihypertensive drug(s) 11) Blood biochemical test 1~7: at the time of allograft biopsy 8~11: at the time of allograft biopsy, and 1 and 2 years after allograft biopsy

—

Countries

Japan

Contacts

Public ContactTadashi Sofue

Kagawa University Hospital Department of Nephrology

sofue@med.kagawa-u.ac.jp087-891-2149

Outcome results